ASMB — Assembly Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $80.32m
- -$49.92m
- $7.16m
- 24
- 35
- 76
- 41
Annual cashflow statement for Assembly Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -97.6 | -62.2 | -130 | -93.1 | -61.2 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 23.4 | 28.8 | 49.9 | 10.3 | 7.18 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -9.53 | -30.3 | -11.4 | -2.12 | 76.3 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -84.1 | -63 | -93.4 | -84.5 | 22.7 |
| Capital Expenditures | -1.55 | -2.22 | -3.1 | -0.102 | -0.255 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -48.8 | 70.3 | 29.6 | 90.7 | -68.9 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -50.3 | 68.1 | 26.5 | 90.6 | -69.1 |
| Financing Cash Flow Items | 0.747 | 0.68 | 0.258 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 140 | 7.6 | 53.1 | 0.614 | 13.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.26 | 12.7 | -13.8 | 6.79 | -32.6 |